CURASAN announced the first U.S. implantation of CERASORB® Ortho Foam bone graft.
This marks CURASAN’s entrance into the U.S. orthopedic bone graft substitute market, which the company estimates at over US $800MM in annual sales.
About one year ago, CURASAN’s parent company announced plans for targeted expansion of sales and marketing activities in the U.S. and China. By year-end, CURASAN received FDA 510(k) clearance to market CERASORB Ortho FOAM for the treatment of bone defects in the extremities and pelvis.
CURASAN announced the first U.S. implantation of CERASORB® Ortho Foam bone graft.
This marks CURASAN’s entrance into the U.S. orthopedic bone graft substitute market, which the company estimates at over US $800MM in annual sales.
About one year ago, CURASAN's parent company announced plans for targeted expansion of sales and marketing...
CURASAN announced the first U.S. implantation of CERASORB® Ortho Foam bone graft.
This marks CURASAN’s entrance into the U.S. orthopedic bone graft substitute market, which the company estimates at over US $800MM in annual sales.
About one year ago, CURASAN’s parent company announced plans for targeted expansion of sales and marketing activities in the U.S. and China. By year-end, CURASAN received FDA 510(k) clearance to market CERASORB Ortho FOAM for the treatment of bone defects in the extremities and pelvis.
Copy to clipboard 
